文献速递其他结缔组织病

自体干细胞移植与环磷酰胺治疗系统性硬化症的临床与分子转归:纵向缺失数据处理

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-11-16

在随机分配至环磷酰胺(CYC,n=34)或造血干细胞移植(HSCT,n=33)的系统性硬化症(SSc)患者中,采用混合效应模型和共享参数模型处理纵向缺失数据,比较临床、肺功能和生活质量指标的纵向趋势。结果显示,考虑早期脱落影响后,HSCT组用力肺活量每年增加0.77个百分点,而CYC组每年下降3.70个百分点(P=0.004),且炎症和纤维增殖分子亚型中HSCT长期趋势更优。

要点

  • 处理缺失数据后,HSCT组FVC每年增加0.77个百分点,CYC组每年下降3.70个百分点。
  • HSCT在炎症和纤维增殖亚型中肺功能及生活质量长期趋势优于CYC。
  • 忽视早期脱落可能扭曲长期临床趋势估计。

核心结论

  • 基于两种统计模型估计的纵向趋势证实,在严重SSc中HSCT疗效优于CYC。
  • 未考虑参与者早期脱落可能扭曲长期临床趋势的估计。

研究设计与样本

  • 采用混合效应回归模型(假设数据随机缺失)和共享参数模型(假设数据非随机缺失)估计纵向趋势。
  • 同时分析基于基线基因表达特征定义的SSc内在分子亚型(正常样、炎症、纤维增殖)的纵向趋势。

主要发现

  • 观察到的可用均值显示两组肺功能测试随时间改善,但考虑参与者脱落后的估计不同。
  • HSCT组用力肺活量每年增加0.77个百分点,CYC组每年下降3.70个百分点(P=0.004)。
  • 一氧化碳弥散量和生活质量指标呈现类似结果,两种分析模型结果一致。
  • 炎症亚型(n=20)和纤维增殖亚型(n=20)中,HSCT组肺功能和生活质量长期趋势优于CYC组。
  • 纤维增殖亚型中HSCT组改良Rodnan皮肤厚度评分也优于CYC组;正常样亚型(n=22)中HSCT优势不明显。

关键数值与推荐

  • 用力肺活量年变化:HSCT组+0.77个百分点/年,CYC组-3.70个百分点/年,P=0.004。
  • 分子亚型分组:炎症亚型n=20,纤维增殖亚型n=20,正常样亚型n=22。

临床怎么用

  • 在严重SSc治疗选择中,HSCT较CYC可带来更优的长期肺功能和生活质量趋势。
  • 评估疗效时应考虑早期脱落对纵向趋势估计的潜在影响,避免偏倚。
  • 分子亚型(炎症、纤维增殖)可能有助于识别HSCT获益更明显的人群。

局限性

  • 分析基于随机试验的样本,样本量有限(CYC组34例,HSCT组33例)。
  • 纵向趋势依赖统计模型假设(随机缺失或非随机缺失),可能存在未测量的混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Among individuals with systemic sclerosis (SSc) randomized to cyclophosphamide (CYC) (n = 34) or hematopoietic stem cell transplantation (HSCT) (n = 33), we examined longitudinal trends of clinical, pulmonary function, and quality of life measures while accounting for the influence of early failures on treatment comparisons. METHODS: Assuming that data were missing at random, mixed-effects regression models were used to estimate longitudinal trends for clinical measures when comparing treatment groups. Results were compared to observed means and to longitudinal trends estimated from shared parameter models, assuming that data were missing not at random. Longitudinal trends for SSc intrinsic molecular subsets defined by baseline gene expression signatures (normal-like, inflammatory, and fibroproliferative signatures) were also studied. RESULTS: Available observed means for pulmonary function tests appeared to improve over time in both arms. However, after accounting for participant loss, forced vital capacity in HSCT recipients increased by 0.77 percentage points/year but worsened by -3.70/year for CYC (P = 0.004). Similar results were found for diffusing capacity for carbon monoxide and quality of life indicators. Results for both analytic models were consistent. HSCT recipients in the inflammatory (n = 20) and fibroproliferative (n = 20) subsets had superior long-term trends compared to CYC for pulmonary and quality of life measures. HSCT was also superior for modified Rodnan skin thickness scores in the fibroproliferative subset. For the normal-like subset (n = 22), superiority of HSCT was less apparent. CONCLUSION: Longitudinal trends estimated from 2 statistical models affirm the efficacy of HSCT over CYC in severe SSc. Failure to account for early loss of participants may distort estimated clinical trends over the long term.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Keyes-Elstein L, Pinckney A, Goldmuntz E, et al. Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care Res (Hoboken). 2022. PMID: 34533286. doi:10.1002/acr.24785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。